The Johns Hopkins Comprehensive Neurofibromatosis Center (JHCNC) is part of a national and international collaboration of medical centers and providers seeking to find the best treatments for patients and to advance research. Their goal is to work with patients' primary care doctors to provide a medical home for this life-long, complicated syndrome. Care providers at the Johns Hopkins Comprehensive Neurofibromatosis Center (JHCNC) are part of one of the largest brain and peripheral nerve tumor centers in the world. The clinic is designated as an affiliated clinic of the Children’s Tumor Foundation.
We have expertise in managing neurofibromatosis type 1, neurofibromatosis type 2 and schwannomatosis. With our multidisciplinary team of care providers from several specialties within Johns Hopkins Medicine, we are able to offer patients comprehensive care and management, as well as access to progressive therapies and clinical research opportunities.
What We Treat
NF1 is a common inherited neurological disorder, affecting 1 in every 3,000 people.
NF2 affects about 1 in every 25,000 people and often causes profound hearing loss.
Schwannomatosis is a disorder that presents nerve tumors throughout the body.
New Research Grant
Physician scientists dedicated to researching treatments for plexiform neurofibromas in NF1 may apply for the Francis S. Collins Scholars’ Program in Neurofibromatosis sponsored by the Neurofibromatosis Therapeutic Acceleration Program (NTAP).